从机制到向治疗:进步素乳酸驱动的癌症进展 (综述)
Zhe Jia1, Shan Lu1, Zhenchuan Wang1
1Department of Neurosurgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Oncology letters
|November 24, 2025
概括
基因素乳化,一种代谢-表观遗传链接,驱动癌症的进展和治疗耐药性. 针对这种修改提供了新的治疗策略和预后生物标志物,以改善癌症治疗.
科学领域:
- 生物化学 生物化学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
背景情况:
- 基因素乳化是一种新的翻译后修改,将癌症代谢与表观遗传学联系起来.
- 基因组H3 lysine 18乳化 (H3K18la) 在瘤开始,进展,转移,免疫逃避和治疗耐药性方面至关重要.
研究的目的:
- 阐明质母乳化在癌症中的多面性作用.
- 探索向激素乳化的治疗策略.
- 突出乳化作为生物标志物的临床潜力.
主要方法:
- 审查关于基因素乳化现有的文献.
- 通过基因素乳化调节的途径的分析 (瘤性,代谢性,免疫性).
- 研究治疗干预和生物标志物潜力的研究.
主要成果:
- 希斯乳化调节关键的瘤和代谢途径,影响染色质结构和基因转录.
- H3K18la影响瘤微环境,促进M2巨分化和CD8+T细胞功能障碍,而CD8+T细胞内在乳化可能会增强抗瘤免疫力.
- 希斯酸乳化通过自,DNA修复和铁灭抑制,有助于化学抵抗.
- H3K18la和H4K5la显示出作为预后生物标志物的前景.
结论:
- 基斯乳酸化在癌症的发展,免疫逃避和治疗耐药性方面发挥着重要作用.
- 向乳化通路是一个有前途的治疗途径.
- 需要进一步的研究来澄清非酶机制,确定调节酶,并验证临床应用的疗法.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
02:39lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
02:32Histone Modification
15.9K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
15.9K
02:32Histone Modification
4.3K
4.3K